Archive

Posts tagged under: clinical data

Presenting at the Patient Recruitment and Retention Summit in London, 21-23 February 2017

Our next meeting will happen in London this month: MDCPartners will present at the 9th Annual Patient Recruitment and Retention Summit 2017, which will take place in the London Marriott Hotel Kensington during 21-23 February 2017. Hot topics during this meeting:

  • What role does clinical research have on patients?
  • How to make trials more valuable for patients?
  • New regulations and the impact on clinical trials
  • Developing a robust clinical trial recruitment and retention strategy
  • What makes a good feasibility process?
  • How to keep the site staff motivated and engaged?

Click here to request the full event agenda.

Utilizing Big Data to Enhance Patient Recruitment

On Wednesday 22 February 2017 at 11:45 AM MDCPartners’ Strategic Analyst in Oncology, Dr Jonathan Crowther, will talk about:

Utilizing big data to enhance patient recruitment: Analyzing public information for trial feasibility and site selection

The path to clinical trial success is burdened with underperforming site selection, poor patient recruitment and frequent delays. Such barriers result in failures to meet targets and dwindling statistical significance. Comprehensive planning via a feasibility survey can alleviate these issues however, it has been suggested that the accuracy of a survey may be below 10%. As big data becomes more applicable in the clinical trial setting, capitalizing on the wealth of publicly available clinical data is essential. The clinical business intelligence platform ta-Scan semantically links trial, investigator and site information to provide a robust feasibility analysis to help address the following questions:

  • Estimation of appropriate patient cohorts
  • Key Opinion Leaders in the field
  • Competing and historic trials across the therapeutic area
  • Suitable geographic setting for a trial
  • IRB and timing issues that may affect trial start-up

Join us in London

Would you like to join us in London this month to learn more about how to leverage big data for patient recruitment or to see how our real-world data evidence solutions can help with clinical trial planning challenges? Let us know to arrange a meeting with our Technical Product Manager Kristof Geentjens and our Strategic Analyst in Oncology Dr Jonathan Crowther. Or just pop by at booth #5!

NEWS RELEASE: MDCPartners launches new ta-Scan software that ‘will revolutionize’ the way pharmaceutical companies plan for the future

Antwerp, Belgium | 24 January 2017 – MDCPartners today launches ta-Scan 5, an update of its global web-based platform that analyses clinical trial data. The new platform is set to revolutionize the way pharmaceutical researchers plan for the future, by providing unrivaled insights that will help inform future business decisions.

The new ta-Scan 5 is the first software of its kind to use exceptionally powerful algorithms to analyse clinical data from multiple global public sources in its patented Trial Cloud®. The new version 5 will mean that pharmaceutical companies are able to obtain more valuable insights on clinical research than ever before, via a more streamlined process.

The software will allow companies to go into more detail on clinical trial research than ever before, with access to over 250,000 clinical trials and 7 million scientific and clinical experts. This will provide unique insights on specific compounds, research institutes, clinical centers, patient populations, key investigators and competitor analysis to help strategic decision making.

“We believe the opportunity in clinical business intelligence is the freedom to look at data from multiple sources, from any region, combined into one system that’s easy to use. The new ta-Scan 5 does just that – it taps into vast amounts of information and provides comprehensive analysis that can be broken down easily. Pharmaceutical companies are now starting to realize their opportunities in gathering the most valuable business intelligence, and I believe the ability of this software will fundamentally change the way clinical research is planned and executed across the industry,” comments David Cocker, CSO for MDCPartners, who is presenting this week at the SCOPE Summit in Miami, Florida.

“For the first time ever, MDCPartners has been able to simplify complex trial-related queries and perform deep analysis using the most powerful algorithms yet. Using Real World Solutions, we can link internal and external information together through a portal, to generate a comprehensive landscape and get a full view of where the competing trials are conducted, and where the patient populations are. Before, we couldn’t link this information, now it is at our fingertips,” comments Dr Bart Naudts, Lead Data Architect at MDCPartners.

The ta-Scan web platform has been used by pharmaceutical and biotech researchers for the last decade. It has transformed and advanced the process of intelligence gathering and analyzes across the industry.

Media Enquiries

MDCPartners
Mireille De Cré
mireille.decre@mdcpartners.be
+32 (0) 3 870 97 50

Tonic Life Communications
Stan Jackson / Chrissie Hannah
stan.jackson@toniclc.com / chrissie.hannah@toniclc.com
+44 (0) 774 771 8279 / +44 (0)777 253 4646

***ENDS***

Notes to Editors

About ta-Scan

ta-Scan is an intelligence web platform for clinical development, which analyses data for trial planning, expert profiling, disease landscape and competitive intelligence, for researchers in the pharmaceutical and biotech industry. It was launched nearly a decade ago to transform and advance the intelligence gathering and analyses that enable clinical development.

Powerful algorithms enable researchers to bypass print publications, restrictive registries and dense databases for the insights they need to make evidence-based decisions. With ta-Scan, users can locate key opinion leader (KOL) associations, investigators with specific therapeutic experience, or institutes with the capacity to conduct complex protocols.

To find out more about ta-Scan, please visit: www.ta-scan.com/product

About ta-Scan 5

ta-Scan 5 is the updated model of ta-Scan, which was recently launched by MDCPartners at the SCOPE Summit in Miami, Florida, in January 2017. It offers a uniquely streamlined and simplified intelligence gathering process and improves data access and value, allowing for a more intuitive, business-oriented workflow.

ta-Scan 5 features a refined and robust search engine tool which activates alternative information pathways with the flexibility to adjust query filters with ease. The number and potential combination of trial-related queries is unrestricted, meaning that hundreds of data classes are semantically connected that can be accessed by one query.

To find out  more about ta-Scan 5, please visit: https://vimeo.com/mdcp/ta-scan5

About MDCPartners

Founded in 1999, MDCPartners specialises in business intelligence and strategic consultancy for the pharmaceutical and biotech industry. They combine drug development expertise with the latest data sciences to provide clinical trial optimisation, medical expert identification and competitive intelligence.

MDCPartners is a leader in the field of data mining and semantic processing. With their patented data solutions, their clients transform millions of dispersed data points into meaningful intelligences.

MDCPartners is headquartered in Antwerp, Belgium, with sales offices in the USA and Japan. It has three flagship products for global pharmaceutical data solutions, including:

  • ta-Scan: the flagship product ta-Scan is a web business intelligence platform that analyses clinical development programmes, trial and site data, and involvement of medical experts
  • normScan: the medical device standards monitoring tool, normScan, is tailored to the client’s medical device portfolio. normScan tracks all relevant device standards and regulatory documents that have been published or are in development
  • Real World Solutions: an evolving area of business for MDCPartners are the customised data solutions, which tap into a robust inventory of algorithms and unique visualisation tools. Users can gain optimal insights from data either as stand-alone or combined with public data

To find out more about MDCPartners, please visit: www.mdcpartners.be

Categories

 

Tags

 

Connect with MDCPartners

Follow us on LinkedIn

Follow us on Twitter

Top of Page